CH BIOTECH SER (08037) announced its interim results for 2025, reporting revenue of HK$38.872 million, representing a year-on-year increase of 19.79%. The loss attributable to owners of the company was HK$32.006 million, narrowing by 59.95% compared to the same period last year. Loss per share stood at HK$0.033.

According to the announcement, the improvement in losses was primarily attributed to the company's successful implementation of cost control measures, which led to an increase in gross profit margin and a reduction in administrative expenses. Additionally, the company received compensation income of approximately HK$13.7 million from insurance claims related to damage caused by heavy rainfall to the Hainan construction site in 2024.